Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes | Zendy

Frauke Fehse | Zendy; Michael Trautmann | Zendy; Jens J. Holst | Zendy; Amy E. Halseth | Zendy; Nuwan D. Nanayakkara | Zendy; Loretta L. Nielsen | Zendy; Mark Fineman | Zendy; Dennis Dong Hwan Kim | Zendy; Michael A. Nauck | Zendy

Open Access

Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes

Author(s) -

Frauke Fehse,

Michael Trautmann,

Jens J. Holst,

Amy E. Halseth,

Nuwan D. Nanayakkara,

Loretta L. Nielsen,

Mark Fineman,

Dennis Dong Hwan Kim,

Michael A. Nauck

Publication year - 2005

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2005-1093

Subject(s) - medicine , endocrinology , exenatide , insulin , type 2 diabetes , incretin , diabetes mellitus , metformin , body mass index

First-phase insulin secretion (within 10 min after a sudden rise in plasma glucose) is reduced in type 2 diabetes mellitus (DM2). The incretin mimetic exenatide has glucoregulatory activities in DM2, including glucose-dependent enhancement of insulin secretion.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research